We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2013 by Ann M. Romaker, MD, Romaker & Associates.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01089647
First Posted: March 18, 2010
Last Update Posted: May 30, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Ann M. Romaker, MD, Romaker & Associates
March 17, 2010
March 18, 2010
May 30, 2013
September 2010
June 2013   (Final data collection date for primary outcome measure)
decrease the number of apnea/hypopnea to <5 per hour of sleep [ Time Frame: 3 months ]
by decreasing nasal congestion, we hope to decrease the number of respiratory events per hour of sleep back to the normal range
Same as current
Complete list of historical versions of study NCT01089647 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)
Montelukast and Nasa ICS for Treatment of Mild Obstructive Sleep Apnea in Adults
In children with mild apnea combined therapy with an inhaled nasal steroid and a medication that decreased nasal congestion (montelukast) was shown to be effective. We are testing to see if this combination works in adults with mild apnea as well.
40 adults with mild OSA (< 5 apneas/hypopneas per hour of sleep) will receive either a combination of two medicines that decrease nasal congestion-montelukast and nasal budesonide-or a placebo pill and nasal spray. After 3 months of therapy, a repeat sleep study will be done to determine the differences, if any, in the frequency of sleep disordered breathing in the two groups.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Obstructive Sleep Apnea
  • Drug: budesonide nasal spray and a montelukast pill
    budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
  • Drug: Placebo: sugar pill and salt water nasal spray
    sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
  • Active Comparator: budesonide nasal spray and a montelukast pill
    treatment arm
    Intervention: Drug: budesonide nasal spray and a montelukast pill
  • Placebo Comparator: sugar pill, salt water nasal spray
    placebo
    Intervention: Drug: Placebo: sugar pill and salt water nasal spray
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
40
December 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age 18 - 100 years
  • RDI between 5 - 15
  • all races
  • both sexes

Exclusion Criteria:

  • craniofacial, syndromic, neurological abnormalities
  • current or previous use of Singular, Rhinocort within last 6 months
  • acute upper respiratory infections
  • recent nasal trauma, nasal surgery, nasal septum perforation
  • known immunodeficiency or under going immunosuppressant therapy
  • current therapy with drugs that interact with Montelukast or Budesonide
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01089647
Adult OSA drug study
IISP 37206 ( Other Grant/Funding Number: Merck )
Yes
Not Provided
Not Provided
Ann M. Romaker, MD, Romaker & Associates
Romaker & Associates
Merck Sharp & Dohme Corp.
Principal Investigator: Ann Romaker, MD Romaker & Associates
Romaker & Associates
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP